Ritlecitinib and brepocitinib demonstrate significant improvement in scalp alopecia areata biomarkers
Volume: 149, Issue: 4, Pages: 1318 - 1328
Published: Apr 1, 2022
Abstract
Janus kinase (JAK) inhibitors have shown encouraging results in the treatment of alopecia areata (AA), an autoimmune form of hair loss, in small, uncontrolled studies and case reports.We conducted a biopsy substudy during the randomized, double-blind, placebo-controlled first 24 weeks of a phase 2a clinical trial that evaluated the efficacy and safety of ritlecitinib, an inhibitor of JAK3 and the tyrosine kinase expressed in hepatocellular...
Paper Details
Title
Ritlecitinib and brepocitinib demonstrate significant improvement in scalp alopecia areata biomarkers
Published Date
Apr 1, 2022
Volume
149
Issue
4
Pages
1318 - 1328
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History